ViaCyte is a regenerative medicine company focused on developing a transformative cell replacement therapy to free people with insulin-requiring diabetes from painful and frequent insulin injections, strict diet regimens, constant blood sugar monitoring, and serious chronic health conditions associated with the disease.
ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device. Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels.
Latest funding size
Time since last funding
|a year ago|
|JDRF, Johnson & Johnson Development Corporation, Johnson & Johnson Innovation, W.L. Gore & Associates, Asset Management Partners|